Vident Investment Advisory LLC purchased a new stake in shares of Allergan PLC. (NYSE:AGN) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 1,284 shares of the company’s stock, valued at approximately $307,000.

A number of other hedge funds have also bought and sold shares of AGN. Crestwood Advisors Group LLC acquired a new stake in Allergan PLC. during the first quarter valued at about $103,000. Feltz Wealth PLAN Inc. bought a new position in shares of Allergan PLC. during the first quarter valued at $107,000. Enterprise Financial Services Corp boosted its position in shares of Allergan PLC. by 62.7% in the first quarter. Enterprise Financial Services Corp now owns 462 shares of the company’s stock valued at $110,000 after buying an additional 178 shares during the period. JNBA Financial Advisors boosted its position in shares of Allergan PLC. by 2.5% in the first quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock valued at $116,000 after buying an additional 12 shares during the period. Finally, Webster Bank N. A. boosted its position in shares of Allergan PLC. by 31.0% in the first quarter. Webster Bank N. A. now owns 520 shares of the company’s stock valued at $124,000 after buying an additional 123 shares during the period. 84.66% of the stock is owned by institutional investors and hedge funds.

Allergan PLC. (NYSE:AGN) traded down 3.08% during mid-day trading on Friday, reaching $242.65. The company had a trading volume of 3,014,741 shares. Allergan PLC. has a 1-year low of $184.50 and a 1-year high of $256.80. The company has a market capitalization of $81.50 billion, a PE ratio of 7.56 and a beta of 1.16. The firm has a 50-day moving average of $245.21 and a 200 day moving average of $237.12.

Allergan PLC. (NYSE:AGN) last issued its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, topping the consensus estimate of $3.95 by $0.07. The company had revenue of $4.01 billion during the quarter, compared to analyst estimates of $3.95 billion. Allergan PLC. had a return on equity of 7.29% and a net margin of 82.42%. The firm’s revenue for the quarter was up 8.8% compared to the same quarter last year. During the same period in the prior year, the business posted $3.35 earnings per share. On average, analysts predict that Allergan PLC. will post $16.10 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Investors of record on Friday, August 18th will be given a $0.70 dividend. The ex-dividend date of this dividend is Wednesday, August 16th. This represents a $2.80 annualized dividend and a yield of 1.15%. Allergan PLC.’s payout ratio is 9.63%.

COPYRIGHT VIOLATION WARNING: This story was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another domain, it was stolen and republished in violation of US and international trademark and copyright law. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/08/04/vident-investment-advisory-llc-invests-307000-in-allergan-plc-nyseagn-updated-updated-updated.html.

AGN has been the topic of several recent analyst reports. Goldman Sachs Group, Inc. (The) cut Allergan PLC. from a “buy” rating to a “neutral” rating and set a $262.00 price objective on the stock. in a research note on Wednesday, May 10th. Sanford C. Bernstein reiterated an “outperform” rating on shares of Allergan PLC. in a research note on Thursday, May 25th. Zacks Investment Research upgraded Allergan PLC. from a “hold” rating to a “buy” rating and set a $270.00 target price on the stock in a research note on Tuesday, July 11th. Royal Bank Of Canada set a $279.00 target price on Allergan PLC. and gave the stock a “buy” rating in a research note on Wednesday, April 12th. Finally, Citigroup Inc. lifted their target price on Allergan PLC. to $261.00 and gave the stock a “buy” rating in a research note on Monday, April 24th. Seven research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $274.04.

In related news, Director Nesli Basgoz sold 1,889 shares of the stock in a transaction that occurred on Thursday, May 18th. The stock was sold at an average price of $220.45, for a total value of $416,430.05. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.36% of the company’s stock.

About Allergan PLC.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Stock Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related stocks with our FREE daily email newsletter.